Elestat (epinastine HCl ophthalmic solution 0.05%) as a therapeutic for allergic conjunctivitis

International Ophthalmology Clinics

Volumn 46, Issue 4, 2006, Pages 87-99

  Trattler, William B ^a   Luchs, Jodi ^b   Majmudar, Parag ^c  

^a Center for Excellence in Eye Care Florida   (United States)

^b South Shore Eye Care   (United States)

^c Chicago Cornea Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPINASTINE; EYE DROPS; LORATADINE; OLOPATADINE;

ALLERGIC CONJUNCTIVITIS; BURNING SENSATION; CLINICAL TRIAL; COUGHING; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUTION; HEADACHE; HUMAN; HYPEREMIA; INFECTION; NONHUMAN; OCULAR PRURITUS; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; RHINITIS; SINUSITIS; TREATMENT INDICATION; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; CONJUNCTIVITIS, ALLERGIC; DIBENZAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE H1 ANTAGONISTS; HUMANS; IMIDAZOLES; OPHTHALMIC SOLUTIONS; TREATMENT OUTCOME;

EID: 33750369448     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000212136.77675.b1     Document Type: Review

References (37)

1. Bielory L. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol. 2000;106:1019-1032.
2. Raizman MB. Recognizing and treating ocular allergy in women. Female Patient. 2003;28:14-19.
3. Wuthrich B, Brignoli R, Canevascini M, et al. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr. 1998;128:139-143.
4. Klein B, Schmit-Eilenberger V, Schwalbe C, et al. Eye allergy symptoms have negative impact on patients' activities and emotions. Poster presented at Annual Meeting of the American Academy of Ophthalmology (AAO), November 15-18, 2003, Anaheim, CA.
5. Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2006;117:S450-S456.
6. McGill JI, Holgate ST, Church MK, et al. Allergic eye disease mechanisms. Br J Ophthalmol. 1998;82:1203-1214.
7. Church MK, McGill JI. Human ocular mast cells. Curr Opin Allergy Clin Immunol. 2002;2:419-422.
8. Abelson MB. Histamine. In: Abelson MB, ed. Allergic Diseases of the Eye. Philadelphia, PA: WB Saunders Co; 2000:57-67.
9. Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol. 1981;99:302-304.
10. Macleod JDA, Anderson DF, Baddeley SM, et al. Immunolocalization of cytokines to mast cells in normal and allergic conjunctiva. Clin Exp Allergy. 1997;27:1328-1334.
11. Fugner A, Bechtel WD, Kuhn FJ, et al. In vitro and in vivo studies of the non-sedating antihistamine epinastine. Arzneimittelforschung. 1988;38:1446-1453.
12. Brubaker K, Wright RC, Yerxa BR, et al. In vitro analysis of the antagonism of the histamine H1 receptor by epinastine: a kinetic comparison with other marketed compounds. Invest Ophthalmol Vis Sci. 2006;47:ARVO E-abstract 4975.
13. Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther. 2004;26:35-47.
14. Friedlaender MH, Sharf L, Breshears D. Control of ocular allergy symptoms by epinastine HCl 0.05% in a conjunctival allergen challenge evaluation. Invest Ophthalmol Vis Sci. 2004;45:ARVO E-abstract 4841.
15. Kamei C, Akagi M, Mio M, et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol. 1992;14:191-205.
16. Matsushita N, Aritake K, Takada A, et al. Pharmacological studies on the novel antiallergic drug HQL-79: II. Elucidation of mechanisms for antiallergic and antiasthmatic effects. Jpn J Pharmacol. 1998;78:11-22.
17. Amon U, Gibbs BF, Buss G, et al. In vitro investigations with the histamine H1 receptor antagonist, epinastine (WAL 801 CL), on isolated human allergic effector cells. Inflamm Res. 2000;49:112-116.
18. Calder VL, Ajayi Y, Galatowicz G. IgE-stimulated cytokine production by human cord blood-derived and conjunctival mast cells: effects of epinastine. Presented at Annual Meeting of the American Academy of Asthma, Allergy, and Immunology (ACAAI), November 4-9, 2005; Anaheim, CA.
19. Kamei C, Mio M, Kitazumi S, et al. Antiallergic effect of epinastine (WAL 801CL) on immediate hypersensitivity reactions: (II) Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects. Immunopharmacol Immunotoxicol. 1992;14:207-218.
20. Ohmori K, Manabe H, Akuta-Ohnuma K. Inhibitory effect of oxatomide on oxygen radical generation and peptide-leukotriene release from guinea pig eosinophils. Arzneimeittelforschung. 1998;48:43-46.
21. Koyhama T, Takizawa H, Akiyama N, et al. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun. 1997;230:125-128.
22. Fukuishi N, Kan T, Hirose K, et al. Inhibitory effect of epinastine on superoxide generation by rat neutrophils. Jpn J Pharmacol. 1995;68:449-452.
23. Kanai K, Asano K, Watanabe S, et al. Epinastine hydrochloride antagonism against interleukin 4-mediated T cell cytokine imbalance in vitro. Intl Arch Allergy Immunol. 2006;140:43-52.
24. Whitcup SM, Bradford R, Lue J, et al. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther. 2004;26:29-34.
25. Brazzell RK, Vix J-M, Boshoff L. Efficacy and tolerability of epinastine ophthalmic solution for treatment of seasonal allergic conjunctivitis: a randomized, double-masked, active-controlled clinical trial. Presented at Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI), November 12-17, 2004, Boston, MA.
26. Monson BK, Rothman JS, Raizman MB. Efficacy of epinastine ophthalmic solution for post-exposure treatment of signs and symptoms of allergic conjunctivitis in cat-sensitive subjects. Presented at Annual Meeting of the American College of Allergy, Asthma, and Immunology, November 12-17, 2004, Boston, MA.
27. Elestat [package insert]. Irvine, CA: Allergan Inc, 2004.
28. Kellerman DJ, Chia VW, Ice C. Comprehensive review of the in vivo ocular tolerability and safety of ELESTAT (epinastine ophthalmic solution, 0.05%). Presented at Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI), November 4-9, 2005, Anaheim, CA.
29. Brar B, Vangyi C, Tarlo K, et al. Preclinical safety of ophthalmic epinastine in rabbits and monkeys. Presented at Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), May 5-10, 2002, Ft. Lauderdale, FL.
30. Stern ME, Beuerman RW, Pflugfelder SC. The normal tear film and ocular surface. In: Pflugfelder SC, Beuerman RW, Stern ME, eds. Dry Eye and Ocular Surface Disorders. New York, NY: Marcel Dekker, Inc; 2004:41-62.
31. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490-496.
32. Bielory L, Lien K, Bigelson S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs. 2005;65:215-228.
33. Ousler GW, Wilcox KA, Gupta B, et al. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol. 2004;93:460-464.
34. Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin Ther. 2003;25:931-947.
35. Abelson MB, Gomes PJ, Vogelson CT, et al. Effects of a new formulation of olopatadine ophthalmic solution on nasal symptoms relative to placebo in two studies involving subjects with allergic conjunctivitis or rhinoconjunctivitis. Curr Res Med Opin. 2005;21:683-691.
36. Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. In press.
37. Gilbard JP, Farris RL, Santamaria J. Osmolarity of tear microvolumes in keratoconjunctivitis sicca. Arch Ophthalmol. 1978;96:677-681.